Novavax, Inc., a biotech dedicated to developing next-generation vaccines (including a Phase 3 candidate for COVID-19) has appointed Margaret G. McGlynn, R. Ph. to its board as an independent director.
McGlynn is currently President and Board Chair for HCU Network America, an advocacy organization she founded in 2016 and dedicated to supporting the needs of those impacted by the rare genetic condition homocystinuria (HCU) and related disorders.
McGlynn previously served as President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), and spent more than 20 years at Merck, where she held roles including President of Merck Vaccines and Infectious Diseases, and President, U.S. Hospital and Specialty Products Division.
She currently serves on the boards of directors of Amicus Therapeutics and Vertex Pharmaceuticals.
McGlynn has also served as a Board member for non-profit organizations, including Hilleman Institute for Developing World Vaccine Research, Gavi, the Vaccine Alliance, the Biotechnology Innovation Organization (BIO), and Life Science Cares Philadelphia.
She holds a Bachelor of Science degree in pharmacy, a Master of Business Administration in marketing, and an honorary doctorate from the State University of New York at Buffalo.